• Je něco špatně v tomto záznamu ?

Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review

J. Trojan, L. Mineur, J. Tomášek, E. Rouleau, P. Fabian, G. de Maglio, P. García-Alfonso, G. Aprile, A. Taylor, G. Kafatos, G. Downey, JH. Terwey, JH. van Krieken,

. 2015 ; 10 (10) : e0140717. [pub] 20151022

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020203

BACKGROUND: From 2008-2013, the European indication for panitumumab required that patients' tumor KRAS exon 2 mutation status was known prior to starting treatment. To evaluate physician awareness of panitumumab prescribing information and how physicians prescribe panitumumab in patients with metastatic colorectal cancer (mCRC), two European multi-country, cross-sectional, observational studies were initiated in 2012: a physician survey and a medical records review. The first two out of three planned rounds for each study are reported. METHODS: The primary objective in the physician survey was to estimate the prevalence of KRAS testing, and in the medical records review, it was to evaluate the effect of test results on patterns of panitumumab use. The medical records review study also included a pathologists' survey. RESULTS: In the physician survey, nearly all oncologists (299/301) were aware of the correct panitumumab indication and the need to test patients' tumor KRAS status before treatment with panitumumab. Nearly all oncologists (283/301) had in the past 6 months of clinical practice administered panitumumab correctly to mCRC patients with wild-type KRAS status. In the medical records review, 97.5% of participating oncologists (77/79) conducted a KRAS test for all of their patients prior to prescribing panitumumab. Four patients (1.3%) did not have tumor KRAS mutation status tested prior to starting panitumumab treatment. Approximately one-quarter of patients (85/306) were treated with panitumumab and concurrent oxaliplatin-containing chemotherapy; of these, 83/85 had confirmed wild-type KRAS status prior to starting panitumumab treatment. All 56 referred laboratories that participated used a Conformité Européenne-marked or otherwise validated KRAS detection method, and nearly all (55/56) participated in a quality assurance scheme. CONCLUSIONS: There was a high level of knowledge amongst oncologists around panitumumab prescribing information and the need to test and confirm patients' tumors as being wild-type KRAS prior to treatment with panitumumab, with or without concurrent oxaliplatin-containing therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020203
003      
CZ-PrNML
005      
20160722115953.0
007      
ta
008      
160722s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0140717 $2 doi
024    7_
$a 10.1371/journal.pone.0140717 $2 doi
035    __
$a (PubMed)26491871
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Trojan, Jörg $u University Hospital, Frankfurt, Germany.
245    10
$a Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review / $c J. Trojan, L. Mineur, J. Tomášek, E. Rouleau, P. Fabian, G. de Maglio, P. García-Alfonso, G. Aprile, A. Taylor, G. Kafatos, G. Downey, JH. Terwey, JH. van Krieken,
520    9_
$a BACKGROUND: From 2008-2013, the European indication for panitumumab required that patients' tumor KRAS exon 2 mutation status was known prior to starting treatment. To evaluate physician awareness of panitumumab prescribing information and how physicians prescribe panitumumab in patients with metastatic colorectal cancer (mCRC), two European multi-country, cross-sectional, observational studies were initiated in 2012: a physician survey and a medical records review. The first two out of three planned rounds for each study are reported. METHODS: The primary objective in the physician survey was to estimate the prevalence of KRAS testing, and in the medical records review, it was to evaluate the effect of test results on patterns of panitumumab use. The medical records review study also included a pathologists' survey. RESULTS: In the physician survey, nearly all oncologists (299/301) were aware of the correct panitumumab indication and the need to test patients' tumor KRAS status before treatment with panitumumab. Nearly all oncologists (283/301) had in the past 6 months of clinical practice administered panitumumab correctly to mCRC patients with wild-type KRAS status. In the medical records review, 97.5% of participating oncologists (77/79) conducted a KRAS test for all of their patients prior to prescribing panitumumab. Four patients (1.3%) did not have tumor KRAS mutation status tested prior to starting panitumumab treatment. Approximately one-quarter of patients (85/306) were treated with panitumumab and concurrent oxaliplatin-containing chemotherapy; of these, 83/85 had confirmed wild-type KRAS status prior to starting panitumumab treatment. All 56 referred laboratories that participated used a Conformité Européenne-marked or otherwise validated KRAS detection method, and nearly all (55/56) participated in a quality assurance scheme. CONCLUSIONS: There was a high level of knowledge amongst oncologists around panitumumab prescribing information and the need to test and confirm patients' tumors as being wild-type KRAS prior to treatment with panitumumab, with or without concurrent oxaliplatin-containing therapy.
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    _2
$a kolorektální nádory $x farmakoterapie $x sekundární $7 D015179
650    _2
$a demografie $7 D003710
650    _2
$a exony $x genetika $7 D005091
650    _2
$a ženské pohlaví $7 D005260
650    12
$a zdravotnické přehledy $7 D006306
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a chorobopisy $7 D008499
650    12
$a lékaři $7 D010820
650    _2
$a protoonkogenní proteiny p21(ras) $x genetika $7 D016283
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mineur, Laurent $u Institute Sainte Catherine, Avignon, France.
700    1_
$a Tomášek, Jiří $u Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Rouleau, Etienne $u Curie Institute, Paris, France.
700    1_
$a Fabian, Pavel $u Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a de Maglio, Giovanna $u University and General Hospital, Udine, Italy.
700    1_
$a García-Alfonso, Pilar $u Gregorio Marañón Hospital, Madrid, Spain.
700    1_
$a Aprile, Giuseppe $u University and General Hospital, Udine, Italy. $7 gn_A_00007877
700    1_
$a Taylor, Aliki $u Amgen Ltd, Uxbridge, UK.
700    1_
$a Kafatos, George $u Amgen Ltd, Uxbridge, UK.
700    1_
$a Downey, Gerald $u Amgen Ltd, Uxbridge, UK.
700    1_
$a Terwey, Jan-Henrik $u Amgen (Europe) GmbH, Zug Switzerland.
700    1_
$a van Krieken, J Han $u Radboud University Medical Center, Nijmegen, Netherlands.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 10, č. 10 (2015), s. e0140717
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26491871 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160722120207 $b ABA008
999    __
$a ok $b bmc $g 1154873 $s 944731
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 10 $c 10 $d e0140717 $e 20151022 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Možnosti archivace